Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/28758

Transgenic model evaluation II (Phenolphthalein): Target Organs and Levels of Evidence for GMM-12

Toxicology and Carcinogenesis Study of Phenolphthalein (CASRN 77-09-8) in Genetically Modified Haploinsufficient p16Ink4a/p19Arf Mice (Feed Study)

Chemical (Study Title)
CASRN
Peer Review Date Route/Exposure Levels Study Laboratory
Transgenic model evaluation II (Phenolphthalein)
77-09-8
08/28/2006 Dosed-Feed
0, 200, 375, 750, 3000, or 12000 ppm
Battelle Columbus Laboratory

Levels of evidence information for Carcinogenesis and Genetic Toxicology Studies of Phenolphthalein in Haploinsufficient P16(Ink4a)/(+/-) (C57BL/6) Mice
  Male P16(Ink4a)/(+/-) (C57BL/6) Mice Female P16(Ink4a)/(+/-) (C57BL/6) Mice
  27 Weeks 27 Weeks
Levels of Evidence No Evidence No Evidence
Neoplastic Lesions None None
Non-Neoplastic Lesions
  • Thymus: atypical hyperplasia
  • Testes: germinal epithelium atrophy; interstitial cell hyperplasia
  • Epididymis: hypospermia
  • Kidney: nephropathy; renal tubule hypertrophy
  • Spleen: hematopoietic cell proliferation
  • Thymus: atypical hyperplasia
  • Spleen: hematopoietic cell proliferation